Neurosense Therapeutics Ltd expected to post a loss of 20 cents a share - Earnings Preview

Neurosense Therapeutics

20/03/2024 07:08

* Neurosense Therapeutics Ltd  NRSN.OQ   NRSN.O  is expected
to report resultson March 22 (estimated) for the period ending
December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Neurosense Therapeutics
Ltd is
for a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neurosense
Therapeutics Ltd is $5.25​, above​ its last closing price
of $1.48. ​​​

This summary was machine generated March 20 at 07:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)